All Phenotypes Med1<tm2Jkr> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Med1^tm2Jkr/Med1^tm2Jkr Tg(Alb1-cre)1Dlr/0	involves: 129P2/OlaHsd * C57BL/6	MGI:3511281
cn2	Med1^tm2Jkr/Med1^tm2Jkr A1cf^{Tg(Myh6-cre/Esr1*)1Jmk}/A1cf⁺	involves: 129P2/OlaHsd * FVB/N	MGI:5911329
cn3	Med1^tm2Jkr/Med1^tm2Jkr Tg(Myh6-cre)2182Mds/0	involves: 129P2/OlaHsd * FVB/N	MGI:5911326

Allelic Composition	Med1^tm2Jkr/Med1^tm2Jkr Tg(Alb1-cre)1Dlr/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Med1^tm2Jkr mutation (0 available); any Med1 mutation (83 available)
Tg(Alb1-cre)1Dlr mutation (3 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

liver/biliary system

abnormal hepatocyte morphology ( J:94123 )

• although liver histology was generally normal, hepatocytes were smaller with a larger nuclear volume

• after 2 weeks of treatment with peroxisome proliferators, the expected hypertrophy did not occur except for a few hepatocytes in centrilobular regions

Allelic Composition	Med1^tm2Jkr/Med1^tm2Jkr A1cf^{Tg(Myh6-cre/Esr1*)1Jmk}/A1cf⁺
Genetic Background	involves: 129P2/OlaHsd * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
A1cf^{Tg(Myh6-cre/Esr1*)1Jmk} mutation (5 available); any A1cf mutation (39 available)
Med1^tm2Jkr mutation (0 available); any Med1 mutation (83 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

The Med1^tm2Jkr/Med1^tm2Jkr A1cf^{Tg(Myh6-cre/Esr1*)1Jmk}/A1cf⁺ mouse heart is flaccid and flabby after tamoxifen induction.

mortality/aging

premature death ( J:243730 )

• mice survive between 13 and 28 days after the first day of tamoxifen injection

cardiovascular system

abnormal heart morphology ( J:243730 )

• hearts appear increasingly flaccid by 14 days after first tamoxifen injection

enlarged heart ( J:243730 )

• mice treated with tamoxifen at 7 weeks of age exhibit an increase in heart size by 14 days after first tamoxifen injection

thin ventricular wall ( J:243730 )

• tamoxifen treated mice show thinning of the ventricular walls

dilated heart ventricle ( J:243730 )

• tamoxifen treated mice show dilatation of the right and left ventricular chambers with thinning of the walls and myocardial cells

cardiac interstitial fibrosis ( J:243730 )

• interstitial myocardial fibrosis in tamoxifen-treated hearts

dilated cardiomyopathy ( J:243730 )

decreased cardiac muscle contractility ( J:243730 )

• tamoxifen-treated mice show diminished heart contractility with ejection fraction only 11% vs. 64% in controls and fractional shortening of 4.77% vs. 33.88% in controls

abnormal heart echocardiography feature ( J:243730 )

• echocardiography indicates increased left ventricular end-diastolic internal dimension, and decreased fractional shortening and ejection fraction in tamoxifen treated mice

congestive heart failure ( J:243730 )

• in tamoxifen treated mice

cellular

cardiac interstitial fibrosis ( J:243730 )

• interstitial myocardial fibrosis in tamoxifen-treated hearts

increased cardiomyocyte apoptosis ( J:243730 )

• tamoxifen-treated hearts show enhanced apoptosis, with the number of apoptotic cardiomyocytes increased about 10-fold

muscle

dilated cardiomyopathy ( J:243730 )

decreased cardiac muscle contractility ( J:243730 )

• tamoxifen-treated mice show diminished heart contractility with ejection fraction only 11% vs. 64% in controls and fractional shortening of 4.77% vs. 33.88% in controls

increased cardiomyocyte apoptosis ( J:243730 )

• tamoxifen-treated hearts show enhanced apoptosis, with the number of apoptotic cardiomyocytes increased about 10-fold

growth/size/body

enlarged heart ( J:243730 )

• mice treated with tamoxifen at 7 weeks of age exhibit an increase in heart size by 14 days after first tamoxifen injection

Mouse Models of Human Disease	DO ID	OMIM ID(s)	Ref(s)
congestive heart failure	DOID:6000		J:243730
dilated cardiomyopathy	DOID:12930	OMIM:PS115200	J:243730

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Heart sections of Med1^tm2Jkr/Med1^tm2Jkr Tg(Myh6-cre)2182Mds/0 heart reveal thinning of ventricular walls and dilation of chambers.

mortality/aging

premature death ( J:243730 )

• nearly 100% of mice die within 10 days post weaning

cardiovascular system

abnormal myocardial fiber morphology ( J:243730 )

• lipid vacuoles of differing sizes are seen in cardiomyocytes

• cardiomyocytes show varying mitochondrial abnormalities, with some mitochondria containing lipid droplets and membranous swirls

decreased myocardial fiber mitochondrial DNA content ( J:243730 )

• mitochondrial DNA content is decreased in hearts

dilated heart atrium ( J:243730 )

enlarged heart ( J:243730 )

• size of the heart increases by 22-29 days of age

thin ventricular wall ( J:243730 )

dilated heart ventricle ( J:243730 )

• dilation of right and left ventricular chambers with thinning of the walls and myocardial cells

cardiac interstitial fibrosis ( J:243730 )

dilated cardiomyopathy ( J:243730 )

• dilated cardiomyopathy with atrial and ventricular dilatation

decreased cardiac muscle contractility ( J:243730 )

• at day 29, contractility of heart is diminished with a fractional shortening of 9.47% compared to 41.08% in controls and ejection fraction of 20.7% compared to 74.27% in controls

abnormal heart echocardiography feature ( J:243730 )

• echocardiography shows increased left ventricular end-diastolic internal dimension, decreased fractional shortening, and decreased ejection fraction

congestive heart failure ( J:243730 )

cellular

decreased myocardial fiber mitochondrial DNA content ( J:243730 )

• mitochondrial DNA content is decreased in hearts

cardiac interstitial fibrosis ( J:243730 )

increased cardiomyocyte apoptosis ( J:243730 )

• increase in apoptosis in hearts, with an increase in the percentage of apoptotic cardiomyocytes

homeostasis/metabolism

cardiac edema ( J:243730 )

• heart weight/body weight ratio is increased but dry heart weight is decreased, suggesting edematous heart

pulmonary edema ( J:243730 )

• lung weight/body weight ratio is increased most likely due to pulmonary edema

muscle

abnormal myocardial fiber morphology ( J:243730 )

• lipid vacuoles of differing sizes are seen in cardiomyocytes

• cardiomyocytes show varying mitochondrial abnormalities, with some mitochondria containing lipid droplets and membranous swirls

decreased myocardial fiber mitochondrial DNA content ( J:243730 )

• mitochondrial DNA content is decreased in hearts

dilated cardiomyopathy ( J:243730 )

• dilated cardiomyopathy with atrial and ventricular dilatation

decreased cardiac muscle contractility ( J:243730 )

• at day 29, contractility of heart is diminished with a fractional shortening of 9.47% compared to 41.08% in controls and ejection fraction of 20.7% compared to 74.27% in controls

increased cardiomyocyte apoptosis ( J:243730 )

• increase in apoptosis in hearts, with an increase in the percentage of apoptotic cardiomyocytes

abnormal Z line morphology ( J:243730 )

• irregularities in Z band pattern

respiratory system

pulmonary edema ( J:243730 )

• lung weight/body weight ratio is increased most likely due to pulmonary edema

growth/size/body

enlarged heart ( J:243730 )

• size of the heart increases by 22-29 days of age

Mouse Models of Human Disease	DO ID	OMIM ID(s)	Ref(s)
congestive heart failure	DOID:6000		J:243730
dilated cardiomyopathy	DOID:12930	OMIM:PS115200	J:243730

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 07/05/2024 MGI 6.24